Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Heptares Therapeutics Ltd.

This article was originally published in Start Up

Executive Summary

Heptares Therapeutics has a technology that stabilizes GPCRs when they are removed from the cell membrane--overcoming one of the field's traditional challenges and allowing scientists to more easily study the receptors' structure and how ligands attach to and detach from them. Heptares' trick: introducing point mutations into GPCR genes that make them less flexible and likely to deform when removed from the cell wall. Heptares is going after small-molecule and antibody drugs in CNS and metabolic diseases.

Related Content


Related Companies

Related Deals

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts